Herein, we tested the combination of metformin with CP treatment and we observed an additive anti-cancer effects when targeting NSCLC cell lines, which we think is partially mediated through IGF-1R down-regulation and signaling attenuation. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.